Medically, you might be interested in...
A regular series on the latest clinical studies from around the world – and what they mean ‘in practice’ – compiled and written by Clare GP Dr Ray O’Connor
Source: imt.ie
Pharmetrics Plus News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pharmetrics Plus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pharmetrics Plus Today - Breaking & Trending Today
GLP-1 Agonist Use for Weight Loss Linked to Gastrointestinal Adverse Events
Users of GLP-1 agonists for weight loss, compared with bupropion-naltrexone, experienced higher rates of gastrointestinal adverse events.
Source: endocrinologyadvisor.com
Major GI Events Rare but Real in Weight-Loss Patients on GLP-1 Drugs
Serious side effects add up at a population level, and are more common than those seen for bupropion-naltrexone, authors say.
Source: tctmd.com
Ozempic-like meds linked to higher risk of pancreatitis, 'stomach paralysis' than other weight-loss drugs
GLP-1 agonists like Ozempic come with a higher risk of severe GI issues than a different common weight-loss drug does.
Source: livescience.com
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA
This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastroi
Source: jamanetwork.com